【藥品庫存】 本藥品為臨時採購藥品，經院長核可後，限定特定科別、病人使用。

Add-on maintenance treatment of severe asthma in adults and children ≥12 years of age with an eosinophilic phenotype

Interleukin-5 Receptor Antagonist; Monoclonal Antibody, Anti-Asthmatic

Distribution: 3.1 L (central); 2.5 L (peripheral)
Metabolism: proteolytic degradation via enzymes that are widely distributed in the body and not restricted to hepatic tissue.
Bioavailability: ~59%
Half-life elimination: ~15.5 days
Excretion: Nonrenal

Hypersensitivity to benralizumab or any component of the formulation

The lowest exposure would be expected during the period of organogenesis.

It is not known if benralizumab is present in breast milk; however, IgG is excreted in human milk and excretion of benralizumab is expected.

Common:
Antibody development, headache, pharyngitis, fever
Postmarketing:
Anaphylaxis, angioedema, hypersensitivity reaction

Severe Asthma for adults
SubQ: 30 mg every 4 weeks for the first 3 doses, and then once every 8 weeks.

Add-on maintenance therapy for children ≥12 years and Adolescents
SubQ: 30 mg every 4 weeks for the first 3 doses then once every 8 weeks

There are no dosage adjustments provided in the manufacturer's labeling (has not been studied)

There are no dosage adjustments provided in the manufacturer's labeling (has not been studied)